SCHEMBL1768481

SCHEMBL1768481

COc1ccc(C(=O)NCc2noc(-c3c4ccccc4nn3CCn3ccnc3)n2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN1A P35498 2/20 0.71
SCN4A P35499 2/20 0.71
SCN5A Q14524 2/20 0.71
SCN9A Q15858 2/20 0.71
SCN2A Q99250 2/20 0.71
SCN3A Q9NY46 2/20 0.71
SCN8A Q9UQD0 2/20 0.71
SCN10A Q9Y5Y9 2/20 0.71
ALDH1A1 P00352 2/20 0.50
TSHR P16473 2/20 0.50
MAPT P10636 1/20 0.50
NAMPT P43490 4/20 0.46
MAPK1 P28482 2/20 0.46
TP53 P04637 1/20 0.46
PTGER4 P35408 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
WDR5 P61964 2/20 0.43
KDM4E B2RXH2 1/20 0.42
PKM P14618 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13582897 0.92 SCN1A (0.82) SCN1ASCN4ASCN5ASCN9ASCN2A
SCHEMBL12648966 0.91 SCN8A (0.76) SCN1ASCN4ASCN5ASCN9ASCN2A
SCHEMBL1768487 0.90 SCN1A (0.85) SCN1ASCN4ASCN5ASCN9ASCN2A
SCHEMBL1768250 0.90 SCN8A (0.70) SCN1ASCN4ASCN5ASCN9ASCN2A
SCHEMBL1768221 0.89 SCN8A (0.67) SCN1ASCN4ASCN5ASCN9ASCN2A
SCHEMBL1768225 0.89 SCN8A (0.76) SCN1ASCN4ASCN5ASCN9ASCN2A
SCHEMBL1768322 0.88 SCN1A (0.66) SCN1ASCN4ASCN5ASCN9ASCN2A
SCHEMBL1768420 0.86 SCN8A (0.76) SCN1ASCN4ASCN5ASCN9ASCN2A
SCHEMBL11896994 0.85 SCN8A (0.67) SCN1ASCN4ASCN5ASCN9ASCN2A
SCHEMBL13583699 0.85 SCN1A (0.64) SCN1ASCN4ASCN5ASCN9ASCN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120283295-A1 INDAZOLE DERIVATIVES AND THEIR USE FOR BLOCKADING VOLTAGE DEPENDENT SODIUM CHANNELS UNIVERSITY COLLEGE LONDON (GB) 2012-11-08 US disclosed
US-20120283295-A1 INDAZOLE DERIVATIVES AND THEIR USE FOR BLOCKADING VOLTAGE DEPENDENT SODIUM CHANNELS UNIVERSITY COLLEGE LONDON (GB) 2012-11-08 US disclosed
US-20120283295-A1 INDAZOLE DERIVATIVES AND THEIR USE FOR BLOCKADING VOLTAGE DEPENDENT SODIUM CHANNELS UNIVERSITY COLLEGE LONDON (GB) 2012-11-08 US disclosed
EP-2483270-A1 INDAZOLE DERIVATIVES AND THEIR USE FOR BLOCKADING VOLTAGE DEPENDENT SODIUM CHANNELS University College London (GB) 2012-08-08 EP disclosed
WO-2011061469-A1 INDAZOLE DERIVATIVES AND THEIR USE FOR BLOCKADING VOLTAGE DEPENDENT SODIUM CHANNELS UNIVERSITY COLLEGE LONDON (GB) 2011-05-26 WO disclosed
WO-2011061469-A1 INDAZOLE DERIVATIVES AND THEIR USE FOR BLOCKADING VOLTAGE DEPENDENT SODIUM CHANNELS UNIVERSITY COLLEGE LONDON (GB) 2011-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283295-A1 INDAZOLE DERIVATIVES AND THEIR USE FOR BLOCKADING VOLTAGE DEPENDENT SODIUM CHANNELS SCN3A, CACNB3, CACNA1B SCN1A 11/4885SCN4A 59/4885SCN5A 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.